

Nicola Coppola

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/429578/nicola-coppola-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236
papers

4,996
citations

36
h-index

57
g-index

249
ext. papers

6,135
ext. citations

6.4
avg, IF

5.65
L-index

#	Paper	IF	Citations
236	Olfactory loss and brain connectivity after COVID-19.. <i>Human Brain Mapping</i> , 2022 ,	5.9	4
235	Meet-Test-Treat for HCV management: patients and clinicians preferences in hospital and drug addiction services in Italy.. <i>BMC Infectious Diseases</i> , 2022 , 22, 3	4	1
234	Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 160-165	6.7	19
233	Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease.. <i>Vaccines</i> , 2022 , 10,	5.3	0
232	Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.. <i>Neurological Sciences</i> , 2022 , 1	3.5	0
231	Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.. <i>PLoS ONE</i> , 2022 , 17, e0265178	3.7	
230	SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis.. <i>Infection</i> , 2022 , 1	5.8	1
229	Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 60, 103724	4	1
228	Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 868286	5	
227	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020.. <i>Scientific Reports</i> , 2022 , 12, 5736	4.9	1
226	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022 , 11,	4.9	2
225	Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project.. <i>Journal of Infection and Public Health</i> , 2022 , 15, 562-565	7.4	1
224	Epidemiological, Clinical and Microbiological Characteristics of Patients with Bloodstream Infections Due to Carbapenem-Resistant <i>K. pneumoniae</i> in Southern Italy: A Multicentre Study. <i>Antibiotics</i> , 2022 , 11, 633	4.9	2
223	Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1323, 115-147	3.6	2
222	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
221	The Impact of the SARS-Cov2 Pandemic on a Persuasive Educational Antimicrobial Stewardship Program in a University Hospital in Southern Italy: A Pre-Post Study. <i>Antibiotics</i> , 2021 , 10,	4.9	1
220	Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7271-7284	5.6	2

219	Delirium and Cognitive Impairment as Predisposing Factors of COVID-19 Infection in Neuropsychiatric Patients: A Narrative Review. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	4
218	Clinical characterization of gingival type of burning mouth syndrome: a cross-sectional study. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2021 , 26, e802-e807	2.6	0
217	Impact of an Education-Based Antimicrobial Stewardship Program on the Appropriateness of Antibiotic Prescribing: Results of a Multicenter Observational Study. <i>Antibiotics</i> , 2021 , 10,	4.9	3
216	Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. <i>Viruses</i> , 2021 , 13,	6.2	1
215	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life R Liver Network Activity (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1057-1063	4.2	
214	Renal Involvement in COVID-19: A Review of the Literature. <i>Infection and Drug Resistance</i> , 2021 , 14, 895-903	4.03	7
213	More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study. <i>Frontiers in Oncology</i> , 2021 , 11, 662746	5.3	7
212	Inappropriateness of Antibiotic Prescribing in Medical, Surgical and Intensive Care Units: Results of a Multicentre Observational Study. <i>Life</i> , 2021 , 11,	3	1
211	Antibiotic resistance in diabetic foot infection: how it changed with COVID-19 pandemic in a tertiary care center. <i>Diabetes Research and Clinical Practice</i> , 2021 , 175, 108797	7.4	6
210	Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 698184	5.3	3
209	Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 830-837	9.5	5
208	Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. <i>Neurological Sciences</i> , 2021 , 42, 3523-3526	3.5	24
207	A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study. <i>Journal of Medical Virology</i> , 2021 , 93, 983-994	19.7	30
206	Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 28-35	9.5	3
205	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 607-614	5.3	3
204	Anticoagulant treatment in COVID-19: a narrative review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 642-648	5.1	34
203	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021 , 93, 1276-1287	19.7	11
202	HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. <i>Life</i> , 2021 , 11,	3	7

201	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
200	Efficacy of Unsupervised Self-Collected Mid-Turbinate FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). <i>Viruses</i> , 2021 , 13,	6.2	1
199	Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma.. <i>Infection and Drug Resistance</i> , 2021 , 14, 5199-5208	4.2	2
198	Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.. <i>Journal of Chemotherapy</i> , 2021 , 1-7	2.3	0
197	Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic. <i>Blood Transfusion</i> , 2021 ,	3.6	
196	Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 941-947	3.4	5
195	Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. <i>Diabetes Care</i> , 2020 , 43, 1408-1415	14.6	225
194	Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient. <i>Journal of Infection</i> , 2020 , 81, 979-997	18.9	11
193	Hyperglycaemia on admission to hospital and COVID-19. <i>Diabetologia</i> , 2020 , 63, 2486-2487	10.3	44
192	Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106067	14.3	1
191	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). <i>Medicine (United States)</i> , 2020 , 99, e18948	1.8	4
190	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. <i>Viruses</i> , 2020 , 12,	6.2	4
189	Blood-borne chronic viral infections in a large cohort of immigrants in southern Italy: A seven-centre, prospective, screening study. <i>Travel Medicine and Infectious Disease</i> , 2020 , 35, 101551	8.4	3
188	Prevalence of occult HBV infection in Western countries. <i>Journal of Medical Virology</i> , 2020 , 92, 2917	19.7	1
187	DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study. <i>Antiviral Therapy</i> , 2020 , 25, 193-201	1.6	3
186	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. <i>Life</i> , 2020 , 11,	3	4
185	Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2. <i>Infection and Drug Resistance</i> , 2020 , 13, 4501-4507	4.2	0
184	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. <i>Diabetes and Metabolism</i> , 2020 , 46, 403-405	5.4	70

183	The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 782.e1-782.e6	9.5	12
182	An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 415-427	3.4	7
181	Burden, risk assessment, surveillance and management of SARS-CoV-2 infection in health workers: a scoping review. <i>Infectious Diseases of Poverty</i> , 2020 , 9, 139	10.4	23
180	Clinical Presentation of COVID-19: Case Series and Review of the Literature. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	29
179	Perioperative Antibiotic Prophylaxis: Knowledge and Attitudes among Resident Physicians in Italy. <i>Antibiotics</i> , 2020 , 9,	4.9	4
178	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , 2020 , 1, 12-24	0.8	1
177	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3349-3358	5.1	7
176	Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review. <i>Infection and Drug Resistance</i> , 2020 , 13, 2657-2665	4.2	40
175	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020 , 10,	3	4
174	Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?. <i>Life</i> , 2020 , 10,	3	3
173	Innovative procedures for micro-elimination of HCV infection in persons who use drugs. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1437-1443	3.4	8
172	Acute kidney injury in COVID-19: a case-report. <i>International Urology and Nephrology</i> , 2020 , 52, 2213-2214	4.3	3
171	Epidemiological and etiological variations in hepatocellular carcinoma. <i>Infection</i> , 2020 , 48, 7-17	5.8	64
170	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019 , 17, 292	8.5	26
169	Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 735-740	14.3	30
168	Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). <i>Viruses</i> , 2019 , 11,	6.2	15
167	Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys. <i>European Journal of Internal Medicine</i> , 2019 , 61, 40-43	3.9	3
166	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019 , 39, 1852-1859	7.9	21

165	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019 , 71, 397-408	13.4	163
164	Epidemiology and management of hepatitis C virus infections in immigrant populations. <i>Infectious Diseases of Poverty</i> , 2019 , 8, 17	10.4	24
163	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019 , 24, 485-493	1.6	3
162	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 846-855	3.4	8
161	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. <i>Journal of Nephrology</i> , 2019 , 32, 763-773	4.8	10
160	HDV infection in immigrant populations. <i>Journal of Medical Virology</i> , 2019 , 91, 2049-2058	19.7	6
159	Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis. <i>Acta Biomedica</i> , 2019 , 90, 187-196	3.2	4
158	Screening for infectious diseases in newly arrived asymptomatic immigrants in southern Italy. <i>Eastern Mediterranean Health Journal</i> , 2019 , 25, 246-253	1.7	2
157	Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. <i>World Journal of Gastroenterology</i> , 2019 , 25, 3299-3312	5.6	19
156	Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). <i>Hepatology International</i> , 2019 , 13, 66-74	8.8	31
155	Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. <i>Liver International</i> , 2019 , 39, 844-853	7.9	3
154	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-138	5.3	5
153	The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. <i>Digestive and Liver Disease</i> , 2019 , 51, 434-437	3.3	9
152	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019 , 39, 484-493	7.9	8
151	HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era. <i>Antiviral Therapy</i> , 2018 , 23, 605-609	6.0	4
150	Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 676-681	2.2	5
149	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 920-929	3.4	2
148	Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 172-180	18.8	95

147	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018 , 90, 942-950	19.7	12
146	Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 198-204	3.4	11
145	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1123-1130	4	11
144	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
143	In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection. <i>HIV Medicine</i> , 2018 , 19, 597-604	2.7	3
142	Management of HBV reactivation in non-oncological patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 611-624	5.5	7
141	Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection. <i>Frontiers in Immunology</i> , 2018 , 9, 1334	8.4	8
140	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. <i>BMC Infectious Diseases</i> , 2018 , 18, 251	4	20
139	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018 , 10,	6.2	3
138	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. <i>Infection</i> , 2018 , 46, 761-783	5.8	15
137	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30
136	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. <i>Saudi Journal of Gastroenterology</i> , 2018 , 24, 25-29	3	11
135	Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. <i>Infection</i> , 2018 , 46, 93-101	5.8	12
134	Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. <i>Annals of Hepatology</i> , 2018 , 17, 47-53	3.1	11
133	Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018 , 10, 558-570	3.4	18
132	HBV molecular epidemiology and clinical condition of immigrants living in Italy. <i>Infection</i> , 2018 , 46, 523-538	5.3	7
131	Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy. <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006601	4.8	6
130	Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. <i>New Microbiologica</i> , 2018 , 41, 26-29	1.1	12

129	No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. <i>Infezioni in Medicina</i> , 2018 , 26, 244-248	3.6	2
128	Prevalence and associated risk factors of latent tuberculosis infection among undergraduate and postgraduate dental students: A retrospective study. <i>Archives of Environmental and Occupational Health</i> , 2017 , 72, 99-105	2	8
127	Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. <i>Infectious Diseases of Poverty</i> , 2017 , 6, 33	10.4	38
126	Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 777.e1-777.e4	9.5	5
125	Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1800-1802	6.9	14
124	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study. <i>Journal of Medical Virology</i> , 2017 , 89, 2138-2143	19.7	9
123	Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples. <i>Journal of Medical Virology</i> , 2017 , 89, 1015-1024	19.7	10
122	Suture thread check test for detection of surgical site contamination: a prospective study. <i>Journal of Surgical Research</i> , 2017 , 220, 268-274	2.5	3
121	ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. <i>Antiviral Therapy</i> , 2017 , 22, 551-558	1.6	11
120	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. <i>PLoS ONE</i> , 2017 , 12, e0181890	3.7	7
119	Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks. <i>Journal of Medical Virology</i> , 2017 , 89, 1931-1936	19.7	12
118	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 885-890	9.5	56
117	Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. <i>Oncotarget</i> , 2017 , 8, 25289-25299	3.3	28
116	Hepatitis B Virus Genotypes, Epidemiological Characteristics, and Clinical Presentation of HBV Chronic Infection in Immigrant Populations Living in Southern Italy. <i>Hepatitis Monthly</i> , 2017 , 17,	1.8	5
115	An update on the treatment options for HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1691-1702	4	19
114	HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 620-8	6.1	26
113	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. <i>Digestive and Liver Disease</i> , 2016 , 48, 1364-1369	3.3	5
112	Prevalence of latent tuberculosis infection in healthcare workers at a hospital in Naples, Italy, a low-incidence country. <i>Journal of Occupational Medicine and Toxicology</i> , 2016 , 11, 53	2.7	5

111	Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. <i>Medicine (United States)</i> , 2016 , 95, e4311	1.8	25
110	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. <i>Digestive and Liver Disease</i> , 2016 , 48, 1066-71	3.3	25
109	Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 372-378	9.5	14
108	Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1897-905	7	33
107	□Treatment of chronic HBV infection in developing countries. <i>Annals of Hepatology</i> , 2016 , 15, 816-823	3.1	4
106	Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. <i>Oncotarget</i> , 2016 , 7, 62706-62714	3.3	38
105	TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8509-8518	5.6	9
104	Hepatitis B virus and hepatitis C virus infection in healthcare workers. <i>World Journal of Hepatology</i> , 2016 , 8, 273-81	3.4	45
103	Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. <i>Journal of Medical Virology</i> , 2016 , 88, 1659-71	19.7	21
102	Dermoscopy of dermatofibrosarcoma protuberans on black skin. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, e119-20	4.5	5
101	The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. <i>BMC Infectious Diseases</i> , 2015 , 15, 149	4	29
100	The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 609.e1-4	9.5	7
99	The reactivation of occult HBV infection emerging with the case of acute hepatitis B in the wife of a subject treated with rituximab-based chemotherapy. <i>Antiviral Therapy</i> , 2015 , 20, 349-52	1.6	4
98	Vaccination against hepatitis b virus: are Italian medical students sufficiently protected after the public vaccination programme?. <i>Journal of Occupational Medicine and Toxicology</i> , 2015 , 10, 41	2.7	36
97	Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model. <i>Journal of Cellular Biochemistry</i> , 2015 , 116, 2188-94	4.7	20
96	Hepatitis B virus infection in immigrant populations. <i>World Journal of Hepatology</i> , 2015 , 7, 2955-61	3.4	30
95	Clinical significance of hepatitis B surface antigen mutants. <i>World Journal of Hepatology</i> , 2015 , 7, 2729-33	3.4	53
94	Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. <i>World Journal of Hepatology</i> , 2015 , 7, 2323-30	3.4	53

93	Hepatitis B virus burden in developing countries. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11941-53	5.6	132
92	Role of occult hepatitis B virus infection in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11931-40	5.6	33
91	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3005-10	4	10
90	Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. <i>Virology Journal</i> , 2015 , 12, 186	6.1	32
89	TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. <i>Liver International</i> , 2015 , 35, 1959-63	7.9	43
88	Role of genetic polymorphisms in hepatitis C virus chronic infection. <i>World Journal of Clinical Cases</i> , 2015 , 3, 807-22	1.6	12
87	Synchronous and metachronous gastric gist with pancreatic adenocarcinoma: report of 2 cases and a review of literature. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015 , 8, 298-301	1.2	2
86	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. <i>Eurosurveillance</i> , 2015 , 20, 30009	19.8	52
85	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10749-59	5.6	19
84	Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. <i>World Journal of Hepatology</i> , 2015 , 7, 2510-21	3.4	12
83	Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. <i>World Journal of Virology</i> , 2015 , 4, 1-12	6.9	17
82	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015 , 14, 325-32	3.1	
81	The impact of viral molecular diversity on the clinical presentation and outcome of acute hepatitis B in Italy. <i>New Microbiologica</i> , 2015 , 38, 137-47	1.1	13
80	Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. <i>Infezioni in Medicina</i> , 2015 , 23, 134-9	3.6	3
79	Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant. <i>Infezioni in Medicina</i> , 2015 , 23, 285-7	3.6	
78	Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. <i>Infection</i> , 2014 , 42, 601-10	5.8	19
77	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1211-23	5.9	27
76	Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014 , 33, 559-67	5.3	30

75	Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region. <i>Journal of Medical Virology</i> , 2014 , 86, 1683-93	19.7	16
74	Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 334-40	6.9	40
73	Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Brazilian Journal of Infectious Diseases</i> , 2014 , 18, 164-9	2.8	8
72	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1337-49	4	21
71	Clinical and virological characteristics associated with severe acute hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O991-7	9.5	18
70	Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. <i>World Journal of Hepatology</i> , 2014 , 6, 384-93	3.4	42
69	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 493-504	2.9	22
68	Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7635-43	5.6	70
67	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 20-26	3.1	24
66	Prevalence of latent tuberculosis infection and associated risk factors among 3,374 healthcare students in Italy. <i>Journal of Occupational Medicine and Toxicology</i> , 2014 , 9, 34	2.7	11
65	GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014 , 12, 1179-86	5.5	10
64	Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT). <i>Infection</i> , 2014 , 42, 811-5	5.8	6
63	Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. <i>Intervirology</i> , 2014 , 57, 311-8	2.5	19
62	PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. <i>International Journal of Cardiology</i> , 2014 , 172, 291-2	3.2	3
61	Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. <i>Biochemical and Biophysical Research Communications</i> , 2014 , 449, 141-5	3.4	37
60	Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. <i>PLoS ONE</i> , 2014 , 9, e94542	3.7	30
59	Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e99450	3.7	13
58	Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. <i>Current Medicinal Chemistry</i> , 2014 , 21, 1391-404	4.3	35

57	Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6707-15	5.6	13
56	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014 , 6, 677-84	3.4	14
55	Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV mono-infection. <i>Infection</i> , 2013 , 41, 959-67	5.8	20
54	Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. <i>Infection</i> , 2013 , 41, 225-9	5.8	34
53	Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1174-1180.e11	6.9	44
52	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013 , 67, 322-8	18.9	23
51	HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. <i>Journal of Clinical Virology</i> , 2013 , 58, 315-7	14.5	26
50	Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. <i>Journal of Clinical Virology</i> , 2013 , 58, 748-50	14.5	11
49	A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2013 , 13, e8352	1.8	22
48	Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. <i>Intervirology</i> , 2013 , 56, 206-12	2.5	31
47	Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 517-23	3.4	44
46	Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. <i>PLoS ONE</i> , 2013 , 8, e65336	3.7	62
45	Absence of occult HCV infection in patients experiencing an immunodepression condition. <i>Infezioni in Medicina</i> , 2013 , 21, 296-301	3.6	20
44	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2013 , 13, 20-6	3.1	11
43	Absence of occult HCV infection in HIV-positive patients. <i>Journal of Infection</i> , 2012 , 64, 436-7	18.9	2
42	Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 890-6	3.4	13
41	Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. <i>Digestive and Liver Disease</i> , 2012 , 44, 49-54	3.3	60
40	Efficacy of Pegylated interferon α 2a and α 2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. <i>BMC Infectious Diseases</i> , 2012 , 12, 357	4	35

39	Virus Variability and Its Impact on HIV and Hepatitis Therapy. <i>Advances in Virology</i> , 2012 , 2012, 607527	1.9	
38	Rituximab-based treatment, HCV replication, and hepatic flares. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 945950		30
37	Impact of comorbidities on the severity of chronic hepatitis B at presentation. <i>World Journal of Gastroenterology</i> , 2012 , 18, 1616-21	5.6	31
36	Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. <i>Antiviral Therapy</i> , 2012 , 17, 1453-8	1.6	11
35	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. <i>Journal of Medical Virology</i> , 2011 , 83, 1909-16	19.7	54
34	Absence of occult hepatitis C virus infection in patients under immunosuppressive therapy for oncohematological diseases. <i>Hepatology</i> , 2011 , 54, 1487-9	11.2	29
33	Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 493-500	3.4	28
32	Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 107-8	3.1	11
31	HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. <i>Hepatology</i> , 2009 , 49, 1090-7	11.2	77
30	Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. <i>Journal of Medical Virology</i> , 2009 , 81, 2012-20	19.7	10
29	Virological and epitope evolution of HCV infection from acute hepatitis C to subsequent episodes of HCV-related acute liver cell necrosis. <i>Infection</i> , 2009 , 37, 344-8	5.8	7
28	Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. <i>Journal of Clinical Virology</i> , 2009 , 46, 222-9	14.5	35
27	Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. <i>Journal of Medical Virology</i> , 2008 , 80, 1547-53	19.7	55
26	Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 307-18	1.6	12
25	Virological Pattern in Plasma, Peripheral Blood Mononuclear Cells and Liver Tissue and Clinical Outcome in Chronic Hepatitis B and C virus Coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 307-318	1.6	27
24	Antiviral treatment of HCV-related cirrhosis. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S96-101	3.3	4
23	Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. <i>Journal of Medical Virology</i> , 2007 , 79, 1679-85	19.7	26
22	Acute hepatitis with severe cholestasis and prolonged clinical course due to hepatitis A virus Ia and Ib coinfection. <i>Clinical Infectious Diseases</i> , 2007 , 44, e73-7	11.6	24

21	Anti-HCV IgG avidity index in acute hepatitis C. <i>Journal of Clinical Virology</i> , 2007 , 40, 110-5	14.5	39
20	Lipodystrophy and serum lipid abnormalities in HIV-positive sub-Saharan population on ART. <i>Journal of Infection</i> , 2006 , 53, e29-33	18.9	9
19	Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1536-43	11.6	22
18	Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. <i>Journal of Clinical Virology</i> , 2006 , 35, 317-20	14.5	42
17	Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. <i>Aids</i> , 2006 , 20, 1253-60	3.5	94
16	Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 67-71	3.4	13
15	Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. <i>Journal of Hepatology</i> , 2005 , 42, 646-51	13.4	29
14	Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. <i>Journal of Medical Virology</i> , 2005 , 75, 222-6	19.7	10
13	The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. <i>Journal of Medical Virology</i> , 2005 , 75, 522-7	19.7	95
12	Influence of chronic coinfection with hepatitis B and C virus on liver histology. <i>Infection</i> , 2004 , 32, 144-8	5.8	75
11	Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 831-833	2.2	3
10	Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 831-3	2.2	8
9	HAV replication in acute hepatitis with typical and atypical clinical course. <i>Journal of Medical Virology</i> , 2003 , 71, 1-6	19.7	31
8	Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. <i>Clinical Infectious Diseases</i> , 2003 , 36, 528-32	11.6	22
7	Helicobacter spp. and liver diseases. <i>Infezioni in Medicina</i> , 2003 , 11, 201-7	3.6	6
6	Absence of Helicobacter spp in the liver of patients with primary or metastatic liver cancer. <i>Hepatology</i> , 2002 , 36, 1300-1	11.2	13
5	HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. <i>Hepatology</i> , 2002 , 36, 1285-91	11.2	106
4	Clinical expression of BilentRhepatitis B virus infection in a patient with visceral leishmaniasis. <i>Infection</i> , 2001 , 29, 166-9	5.8	3

- 3 HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. *Journal of Medical Virology*, **2001**, 64, 350-5 19.7 97
- 2 Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. *Journal of Medical Virology*, **2001**, 65, 681-7 19.7 32
- 1 Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. *Hepatology*, **2000**, 32, 1106-10 11.2 170